HGF/c-Met raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
=== As a soaking agent === Aqueous sulfur dioxide solution is used in corn wet-milling, in the steeping stage of the process. The corn kernels are soaked in this solution in large tanks containing lactic acid and sulfur dioxide at around 53˚C (127˚F) temperature for nearly 40 hours. This is done to soften the kernel so that the oil in the germ will not contaminate other products and is easy to separate.
== Structure == Human M-protein is 165.0 kDa and 1465 amino acids in length. MYOM2 is localized to the human chromosome 8p23.3. M-protein belong to the superfamily of cytoskeletal proteins having immunoglobulin/fibronectin repeats; M-protein contains two immunoglobulin C2-type repeats in the N-terminal region, five fibronectin type III repeats in the central region, and an additional four immunoglobulin C2-type repeats in the C-terminal region. M-protein is expressed only in striated muscle, including fast skeletal muscle and cardiac muscle.
The "Cave of the Painters" (Malerhöhle, 画家窟, Cave 207) is one of the earliest caves of Kizil, and one of the most beautiful. The cave contained a statue of the Buddha against the rear wall of the cella, and a barrel-vaulted ambulatory surrounded it. The main cellar contained nine murals of the preaching Buddha on each side wall. The name of the cave comes from the numerous self-portraits of painters standing at the side of the murals, holding paint cupellas and brushes. Several of the painters have a label, such as the written label in Sanskrit (Gupta script): "Painting of Tutuka" ( Citrakara Tutukasya) next to the painter in question. "Citrakara" is not Tocharian, but Sanskrit (and later Hindi, चित्रकला) for "painter/ painting". In the art of Kizil identifying labels were often added to pictures of donors, but never to narrative scenes. Paleography, stylistic analysis and carbon dating combine to give a date of circa 500 CE for these paintings. Some stylistic elements have a strong Classical touch, such as Roman-style friezes at the top of the walls, over scenes of the Buddha. The Cave of the Painters, as some other caves at Kizil, depicts men in caftans with a triangular collar on the right side, and a unique hairstyle. Another marker is the two-point suspension system for swords, which seems to have been a Hephthalite innovation, and was introduced by them in the territories they controlled. These paintings appear to have been made during Hephthalite rule in the region, circa 480–550 CE.
Sources: en.wikipedia.org
May 24, 2017: Decree on responsibilities delegated to the Secretary of State for Gender Equality. October 2017: Global surge in public speaking out following the Weinstein affair: digital platforms such as Twitter host many testimonies of harassment and sexual assault under hashtags like #MeToo and #BalanceTonPorc in France. August 3, 2018: Law strengthening the fight against sexual and gender-based violence (creation of the offense of sexist insult, broader definition of online harassment, stronger penal provisions on sexual offenses against minors, and a 30-year statute of limitations from the victim's majority for sexual crimes against minors). September 5, 2018: Law on the freedom to choose one's professional future. September 10, 2018: Law on controlled immigration, effective asylum rights, and successful integration. March 23, 2019: Programming and reform law for justice (2018–2022). May 22, 2019: Law on business growth and transformation. May 27, 2019: Decree improving health and maternity coverage for self-employed workers. June 26, 2019: National action plan to eradicate female genital mutilation. July 24, 2019: Bioethics bill including access to medically assisted reproduction (ART) for female couples and single women. July 26, 2019: Law for a trustworthy school. August 6, 2019: Law transforming the civil service. December 28, 2019: Law against domestic violence. March 2020: During the COVID-19 pandemic and lockdowns, domestic violence increased significantly, highlighting the issue in society. June 24, 2020: Law combating online hate content.
Studies have also been conducted on the effect of arsenic trioxide on other cancers. These showed that the drug also induces apoptosis in lung cancer cells (especially in combination with sulindac). The efficacy of arsenic trioxide has also been demonstrated in the treatment of multiple myeloma, in combination with ascorbic acid and bortezomib. Animal studies have shown that the drug also affects ovarian, liver, stomach, prostate, and breast cancers, as well as gliomas and pancreatic cancer (in combination with parthenolide). However, attempts to use arsenic trioxide in the treatment of solid tumors have been limited by the drug's toxicity. Arsenic trioxide also appears promising for treating autoimmune diseases (based on studies in mice).
== Epidemiology == Methemoglobinemia mostly affects infants under 6 months of age (particularly those under 4 months) due to low hepatic production of methemoglobin reductase. The most at-risk populations are those with water sources high in nitrates, such as wells and other water that is not monitored or treated by a water treatment facility. The nitrates can be hazardous to the infants. The link between blue baby syndrome in infants and high nitrate levels is well established for waters exceeding the normal limit of 10 mg/L. However, there is also evidence that breastfeeding is protective in exposed populations.
Day of Defeat received "generally favorable reviews" according to the review aggregation website Metacritic. IGN praised the game for its use of narrow spaces to stimulate the game's "relentless pacing", and GameSpy spoke highly of its attention to detail. Reviewers also praised Day of Defeat for its promotion of teamwork through purposefully tight corridors that force players to cooperate, lest they be killed by an enemy outside their field of vision. Both GameSpy and GameSpot levied criticism against the game for its sub-par visuals and "downright ugly" color palette, blaming the aging GoldSrc engine for the aesthetic issues. Many reviewers drew parallels between Day of Defeat and Battlefield 1942, the latter of which had been released only six months prior to the former. Both games were set in World War II and featured gameplay that was heavily reliant on their respective class-based systems, which lead reviewers to make direct comparisons between the two in their reviews of Day of Defeat. The game was also faulted for its lack of usable vehicles, contrasting Battlefield's usage of operable vehicles as a key gameplay component. PC Gamer US awarded Day of Defeat its 2001 "Mod of the Year" prize. The editors wrote, "Made by amateur developers not yet of American drinking age, Day of Defeat absorbed entire weeks of office LAN play."
Sources: en.wikipedia.org
In such reactions, which are more useful for alkyl iodides and bromides, the degree of alkylation is difficult to control such that one obtains mixtures of primary, secondary, and tertiary amines, as well as quaternary ammonium salts. Selectivity can be improved via the Delépine reaction, although this is rarely employed on an industrial scale. Selectivity is also assured in the Gabriel synthesis, which involves organohalide reacting with potassium phthalimide. Aryl halides are much less reactive toward amines and for that reason are more controllable. A popular way to prepare aryl amines is the Buchwald-Hartwig reaction.
Accounts of exactly what happened vary but it seems likely that he was mockingly offering it to the Labour benches, not, as some alleged, "brandishing" it – an illusion caused by Prior pulling his other arm down. Thatcher was furious. Speaker Thomas suspended the sitting and made Heseltine wait until next day to apologise so that tempers could cool. Heseltine was faced with calls for his resignation from the Shadow Cabinet; he thought it would play well with the public, but in Crick's view it helped to cement a reputation for impulsiveness and poor judgement. In autumn 1976 Heseltine was reshuffled, against his will, to the job of Shadow Environment Secretary. He was particularly cross at having to give up the job of Shadow Industry Secretary to John Biffen. He accepted on condition that he would not have to take the Environment job when the Conservatives returned to office. As Benn had given way to Eric Varley there was no longer such a need for aggressive campaigning on Industry, and Thatcher, who had herself been Shadow Environment Secretary in 1974, wanted him to campaign on council house sales (Heseltine offered up to 50% discounts for tenants who bought their homes) and reform of the rates, as she thought his predecessor Timothy Raison ineffective.
=== Recreational === Benzydamine has been used recreationally. If taken in excess amounts, it acts as an atypical deliriant and CNS stimulant. Such use, particularly among teenagers, has been reported in Brazil, Poland, Romania, and Turkey.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.